Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
- All proposed resolutions approved
- Election of two new Non-Executive Board members
Halle (Saale) / Munich, Germany, June 21, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced the appointment of Kugan Sathiyanandarajah and Professor Dr. Morten Asser Karsdal as Non-Executive members to its Board of Directors. Both appointments were approved during Vivoryon’s Annual General Meeting which took place today. All voting items were passed with a majority.
“We are pleased to welcome Kugan and Morten to Vivoryon’s Board of Directors,” said Dr. Erich Platzer, Chairman of Vivoryon’s Board of Directors. “Morten is a seasoned industry expert, renowned for his seminal contributions to translational and clinical research in biomedical sciences. He has profound expertise in the design and execution of clinical studies as well as a proven track record of successfully developing molecular diagnostics and biomarkers from early-stage development to approval. Kugan’s longstanding career spans many years of holding leading positions in the field of strategic healthcare investments, both in Europe and the U.S. He brings extensive experience in the financial industry to Vivoryon, qualifying as a financial expert due to many years of professional practice. Both new Board members are very well suited to help craft and implement value-creating strategies for the Company as we continue our efforts in bringing new treatment options to patients suffering from Alzheimer’s disease. On behalf of Vivoryon and the Board of Directors, I warmly welcome Morten and Kugan and look forward to working with them.”
Further information on the Company’s AGM, including the voting results on all agenda items, can be found on Vivoryon’s website: https://www.vivoryon.com/annual-general-meeting-2023/
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer’s disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Tel: +1 212-698-8684
Email: [email protected]
Tel: +49 175 8041816
Email: [email protected]